Tanreqing capsule enhances immunity and protects intestinal barrier function in colorectal cancer patients via gut microbiota

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052508

Enrollment

Unknown

Registered

2021-10-30

Start date

2021-11-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cnacer

Interventions

experimental group:Oral Tanreqing capsule

control group:oral placebo

Eligibility

Sex/Gender

All

Age

18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Patients with a histopathological diagnosis of CRC; 2. Aged from 18 to 79 years.

Exclusion criteria

Exclusion criteria: 1. Patients who have received radiotherapy, chemotherapy, immunotherapy; 2. Confirmed metastases or primary tumours in other organs; 3. Patients with a combination of high risk factors such as coronary heart disease, smoking or alcohol consumption; 4. Women who are pregnant or breastfeeding; 5. Those with severe psychiatric disorders who are unable to cooperate with the examination and treatment; 6. Those who are allergic to the drugs used in this trial; 7. Those who have recently taken drugs that may affect immune function; 8. Those who have recently taken antibiotics or probiotics.

Design outcomes

Primary

Measure	Time frame
gut microbiota;lymphocyte subpopulations;carcino-embryonic antigen;	—

Secondary

Measure	Time frame
Ki-67;	—

Countries

China

Contacts

Public ContactZhang Chunze

Tianjin Union Medical Center, Nankai University

chunze.zhang@nankai.edu.cn+86 15922238900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026